Ask AI
ProCE Banner Activity

Integrating CAR T-Cell Therapies for Lymphoma Into Clinical Practice

Slideset

Download these slides for the latest data on CAR T-cell therapies in B-cell lymphomas as presented at an ASH 2025 satellite symposium.

Released: December 04, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This activity aims to improve learners’ knowledge, competence, and performance in application of current and emerging CAR T-cell therapy for patients with various forms of relapsed or refractory B-cell non-Hodgkin lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Demonstrate the ability to select appropriate candidates for CAR T-cell therapy in DLBCL, FL, MCL, and CLL/SLL, applying current evidence and FDA-approved indications

  • Construct comprehensive care plans for patients undergoing CAR T-cell therapy, including referral, pre-treatment preparations, and post-treatment monitoring

  • Formulate evidence-based management strategies for CAR T-cell therapy-related adverse events, including cytokine release syndrome and neurotoxicity

  • Evaluate ongoing clinical trials and emerging data on CAR T-cell therapies for B-cell malignancies to guide appropriate patient enrollment and integrate new findings into clinical practice